Lin Tengjiao, Wang Ke, Yang Deyu, Li Zhichao, Zheng Chuangjie, Chen Xinrong, Zhai Linzhu
Cancer Center, Departments of Radiation Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Guangzhou University of Chinese Medicine, Guangzhou, China.
Front Med (Lausanne). 2025 Mar 26;12:1534956. doi: 10.3389/fmed.2025.1534956. eCollection 2025.
The aim of this study was to compare prognostic factors and survival outcomes in patients with primary central nervous system lymphoma (PCNSL).
The Surveillance, Epidemiology, and End Results (SEER) database was queried for patients diagnosed with PCNSL between 2000 and 2019.
Between 2000 and 2019, a total of 5,812 patients were diagnosed with PCNSL, of whom 2,175 (37%) were ≤ 60 years old and 3,637 (63%) were >60 years old. The younger patients had a higher rate of being diagnosed with stage I-II, a higher rate of receiving chemotherapy and radiotherapy, a similar rate of receiving surgery, and a longer survival time. The most common histological subtype among PCNSL patients was diffuse large B-cell lymphoma (PCNS-DLBCL). Younger PCNS-DLBCL patients who received surgery and chemotherapy exhibited significantly improved overall survival (OS) and disease-specific mortality (DSM) and that African American patients were associated with poorer OS and DSM. Older patients receiving surgery, chemotherapy, and radiotherapy exhibited significantly improved OS and DSM, male and higher Ann Arbor stage were associated with poorer OS and DSM. We created a nomogram for PCNS-DLBCL to predict OS, with a C-index of 0.6749 in the younger cohort and 0.6676 in the older cohort. In the combined therapy analysis, chemotherapy combined with surgical resection had better OS and DSM in all patients.
The two age-stratified cohorts significantly differed in terms of OS and independent influences on OS and DSM. Our constructed nomogram exhibited high accuracy in predicting OS in PCNS-DLBCL patients.
本研究旨在比较原发性中枢神经系统淋巴瘤(PCNSL)患者的预后因素和生存结局。
查询监测、流行病学和最终结果(SEER)数据库中2000年至2019年期间诊断为PCNSL的患者。
2000年至2019年期间,共有5812例患者被诊断为PCNSL,其中2175例(37%)年龄≤60岁,3637例(63%)年龄>60岁。年轻患者I-II期诊断率较高,接受化疗和放疗的比例较高,接受手术的比例相似,生存时间较长。PCNSL患者中最常见的组织学亚型是弥漫性大B细胞淋巴瘤(PCNS-DLBCL)。接受手术和化疗的年轻PCNS-DLBCL患者的总生存期(OS)和疾病特异性死亡率(DSM)显著改善,非裔美国患者的OS和DSM较差。老年患者接受手术、化疗和放疗后OS和DSM显著改善,男性和较高的Ann Arbor分期与较差的OS和DSM相关。我们创建了一个PCNS-DLBCL的列线图来预测OS,年轻队列的C指数为0.6749,老年队列的C指数为0.6676。在联合治疗分析中,化疗联合手术切除在所有患者中具有更好的OS和DSM。
两个年龄分层队列在OS以及对OS和DSM的独立影响方面存在显著差异。我们构建的列线图在预测PCNS-DLBCL患者的OS方面表现出较高的准确性。